nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC2—skin of body—psoriatic arthritis	0.064	0.228	CbGeAlD
Dihydroxyaluminium—VDAC3—skin of body—psoriatic arthritis	0.0533	0.19	CbGeAlD
Dihydroxyaluminium—VDAC1—skin of body—psoriatic arthritis	0.0507	0.181	CbGeAlD
Dihydroxyaluminium—VDAC3—tendon—psoriatic arthritis	0.0406	0.145	CbGeAlD
Dihydroxyaluminium—VDAC1—tendon—psoriatic arthritis	0.0386	0.138	CbGeAlD
Dihydroxyaluminium—Blindness transient—Methotrexate—psoriatic arthritis	0.0379	0.0637	CcSEcCtD
Dihydroxyaluminium—TNNC1—tendon—psoriatic arthritis	0.0331	0.118	CbGeAlD
Dihydroxyaluminium—VDAC1—Fluocinolone Acetonide—Methylprednisolone—psoriatic arthritis	0.0257	0.207	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Fluocinolone Acetonide—Dexamethasone—psoriatic arthritis	0.0253	0.204	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Fluocinolone Acetonide—Betamethasone—psoriatic arthritis	0.0253	0.204	CbGdCrCtD
Dihydroxyaluminium—Electrolyte imbalance—Methylprednisolone—psoriatic arthritis	0.0251	0.0421	CcSEcCtD
Dihydroxyaluminium—VDAC1—Fluocinolone Acetonide—Triamcinolone—psoriatic arthritis	0.0247	0.199	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Fluocinolone Acetonide—Prednisolone—psoriatic arthritis	0.0229	0.185	CbGdCrCtD
Dihydroxyaluminium—Electrolyte imbalance—Betamethasone—psoriatic arthritis	0.0228	0.0382	CcSEcCtD
Dihydroxyaluminium—Electrolyte imbalance—Dexamethasone—psoriatic arthritis	0.0228	0.0382	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Auranofin—psoriatic arthritis	0.0173	0.0291	CcSEcCtD
Dihydroxyaluminium—Extravasation—Betamethasone—psoriatic arthritis	0.0109	0.0183	CcSEcCtD
Dihydroxyaluminium—Extravasation—Dexamethasone—psoriatic arthritis	0.0109	0.0183	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Methotrexate—psoriatic arthritis	0.0108	0.0181	CcSEcCtD
Dihydroxyaluminium—Urticaria—Auranofin—psoriatic arthritis	0.0101	0.017	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Methotrexate—psoriatic arthritis	0.00979	0.0164	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Prednisolone—psoriatic arthritis	0.00957	0.0161	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Triamcinolone—psoriatic arthritis	0.0088	0.0148	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Methylprednisolone—psoriatic arthritis	0.00878	0.0147	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Prednisolone—psoriatic arthritis	0.00874	0.0147	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Auranofin—psoriatic arthritis	0.00873	0.0147	CcSEcCtD
Dihydroxyaluminium—Vomiting—Auranofin—psoriatic arthritis	0.00812	0.0136	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Dexamethasone—psoriatic arthritis	0.00798	0.0134	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Betamethasone—psoriatic arthritis	0.00798	0.0134	CcSEcCtD
Dihydroxyaluminium—Extravasation—Methotrexate—psoriatic arthritis	0.00794	0.0133	CcSEcCtD
Dihydroxyaluminium—Nausea—Auranofin—psoriatic arthritis	0.00758	0.0127	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Betamethasone—psoriatic arthritis	0.00729	0.0122	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Dexamethasone—psoriatic arthritis	0.00729	0.0122	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Prednisone—psoriatic arthritis	0.00695	0.0117	CcSEcCtD
Dihydroxyaluminium—Coma—Methotrexate—psoriatic arthritis	0.00633	0.0106	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Methotrexate—psoriatic arthritis	0.00581	0.00975	CcSEcCtD
Dihydroxyaluminium—Polyuria—Methotrexate—psoriatic arthritis	0.00573	0.00961	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Prednisolone—psoriatic arthritis	0.00552	0.00927	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Methotrexate—psoriatic arthritis	0.00531	0.00891	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Triamcinolone—psoriatic arthritis	0.00528	0.00886	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Methylprednisolone—psoriatic arthritis	0.00527	0.00884	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methylprednisolone—psoriatic arthritis	0.00507	0.0085	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Prednisolone—psoriatic arthritis	0.0047	0.00789	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Dexamethasone—psoriatic arthritis	0.00461	0.00773	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Betamethasone—psoriatic arthritis	0.00461	0.00773	CcSEcCtD
Dihydroxyaluminium—Vertigo—Prednisolone—psoriatic arthritis	0.00448	0.00752	CcSEcCtD
Dihydroxyaluminium—Back pain—Triamcinolone—psoriatic arthritis	0.00444	0.00744	CcSEcCtD
Dihydroxyaluminium—Convulsion—Prednisolone—psoriatic arthritis	0.00432	0.00725	CcSEcCtD
Dihydroxyaluminium—Vertigo—Triamcinolone—psoriatic arthritis	0.00412	0.00691	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methylprednisolone—psoriatic arthritis	0.00411	0.0069	CcSEcCtD
Dihydroxyaluminium—Oedema—Prednisolone—psoriatic arthritis	0.00407	0.00683	CcSEcCtD
Dihydroxyaluminium—Convulsion—Triamcinolone—psoriatic arthritis	0.00397	0.00667	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Prednisolone—psoriatic arthritis	0.00397	0.00667	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methylprednisolone—psoriatic arthritis	0.00396	0.00665	CcSEcCtD
Dihydroxyaluminium—Oedema—Triamcinolone—psoriatic arthritis	0.00374	0.00628	CcSEcCtD
Dihydroxyaluminium—Vertigo—Dexamethasone—psoriatic arthritis	0.00374	0.00627	CcSEcCtD
Dihydroxyaluminium—Vertigo—Betamethasone—psoriatic arthritis	0.00374	0.00627	CcSEcCtD
Dihydroxyaluminium—Infection—Triamcinolone—psoriatic arthritis	0.00372	0.00624	CcSEcCtD
Dihydroxyaluminium—Infection—Methylprednisolone—psoriatic arthritis	0.00371	0.00623	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Triamcinolone—psoriatic arthritis	0.00365	0.00613	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00365	0.00612	CcSEcCtD
Dihydroxyaluminium—Convulsion—Dexamethasone—psoriatic arthritis	0.00361	0.00605	CcSEcCtD
Dihydroxyaluminium—Convulsion—Betamethasone—psoriatic arthritis	0.00361	0.00605	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methylprednisolone—psoriatic arthritis	0.00349	0.00586	CcSEcCtD
Dihydroxyaluminium—Pain—Prednisolone—psoriatic arthritis	0.00348	0.00584	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Prednisone—psoriatic arthritis	0.00342	0.00573	CcSEcCtD
Dihydroxyaluminium—Oedema—Betamethasone—psoriatic arthritis	0.0034	0.0057	CcSEcCtD
Dihydroxyaluminium—Oedema—Dexamethasone—psoriatic arthritis	0.0034	0.0057	CcSEcCtD
Dihydroxyaluminium—Infection—Betamethasone—psoriatic arthritis	0.00337	0.00566	CcSEcCtD
Dihydroxyaluminium—Infection—Dexamethasone—psoriatic arthritis	0.00337	0.00566	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methotrexate—psoriatic arthritis	0.00335	0.00563	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Dexamethasone—psoriatic arthritis	0.00331	0.00556	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Betamethasone—psoriatic arthritis	0.00331	0.00556	CcSEcCtD
Dihydroxyaluminium—Vertigo—Prednisone—psoriatic arthritis	0.00326	0.00546	CcSEcCtD
Dihydroxyaluminium—Urticaria—Prednisolone—psoriatic arthritis	0.00323	0.00543	CcSEcCtD
Dihydroxyaluminium—Pain—Triamcinolone—psoriatic arthritis	0.0032	0.00537	CcSEcCtD
Dihydroxyaluminium—Hypotension—Betamethasone—psoriatic arthritis	0.00317	0.00533	CcSEcCtD
Dihydroxyaluminium—Hypotension—Dexamethasone—psoriatic arthritis	0.00317	0.00533	CcSEcCtD
Dihydroxyaluminium—Convulsion—Prednisone—psoriatic arthritis	0.00314	0.00527	CcSEcCtD
Dihydroxyaluminium—Chills—Methotrexate—psoriatic arthritis	0.00312	0.00524	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Prednisolone—psoriatic arthritis	0.003	0.00503	CcSEcCtD
Dihydroxyaluminium—Urticaria—Triamcinolone—psoriatic arthritis	0.00297	0.00499	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methylprednisolone—psoriatic arthritis	0.00297	0.00498	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00296	0.00497	CcSEcCtD
Dihydroxyaluminium—Oedema—Prednisone—psoriatic arthritis	0.00296	0.00496	CcSEcCtD
Dihydroxyaluminium—Infection—Prednisone—psoriatic arthritis	0.00294	0.00493	CcSEcCtD
Dihydroxyaluminium—Back pain—Methotrexate—psoriatic arthritis	0.00293	0.00492	CcSEcCtD
Dihydroxyaluminium—Pain—Betamethasone—psoriatic arthritis	0.0029	0.00487	CcSEcCtD
Dihydroxyaluminium—Pain—Dexamethasone—psoriatic arthritis	0.0029	0.00487	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Prednisone—psoriatic arthritis	0.00289	0.00484	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Methotrexate—psoriatic arthritis	0.00285	0.00479	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00276	0.00463	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00275	0.00462	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methotrexate—psoriatic arthritis	0.00272	0.00457	CcSEcCtD
Dihydroxyaluminium—Urticaria—Dexamethasone—psoriatic arthritis	0.0027	0.00453	CcSEcCtD
Dihydroxyaluminium—Urticaria—Betamethasone—psoriatic arthritis	0.0027	0.00453	CcSEcCtD
Dihydroxyaluminium—Dizziness—Prednisolone—psoriatic arthritis	0.00269	0.00452	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Betamethasone—psoriatic arthritis	0.00268	0.00451	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Dexamethasone—psoriatic arthritis	0.00268	0.00451	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methotrexate—psoriatic arthritis	0.00262	0.0044	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00256	0.00429	CcSEcCtD
Dihydroxyaluminium—Dizziness—Triamcinolone—psoriatic arthritis	0.00248	0.00415	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methylprednisolone—psoriatic arthritis	0.00247	0.00414	CcSEcCtD
Dihydroxyaluminium—Infection—Methotrexate—psoriatic arthritis	0.00246	0.00412	CcSEcCtD
Dihydroxyaluminium—Nausea—Prednisolone—psoriatic arthritis	0.00242	0.00406	CcSEcCtD
Dihydroxyaluminium—Vomiting—Triamcinolone—psoriatic arthritis	0.00238	0.00399	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methylprednisolone—psoriatic arthritis	0.00237	0.00398	CcSEcCtD
Dihydroxyaluminium—Urticaria—Prednisone—psoriatic arthritis	0.00235	0.00394	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Prednisone—psoriatic arthritis	0.00234	0.00392	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00232	0.0039	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Betamethasone—psoriatic arthritis	0.00232	0.0039	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methotrexate—psoriatic arthritis	0.00231	0.00388	CcSEcCtD
Dihydroxyaluminium—Dizziness—Betamethasone—psoriatic arthritis	0.00225	0.00377	CcSEcCtD
Dihydroxyaluminium—Dizziness—Dexamethasone—psoriatic arthritis	0.00225	0.00377	CcSEcCtD
Dihydroxyaluminium—Nausea—Triamcinolone—psoriatic arthritis	0.00222	0.00373	CcSEcCtD
Dihydroxyaluminium—Nausea—Methylprednisolone—psoriatic arthritis	0.00222	0.00372	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Prednisone—psoriatic arthritis	0.00218	0.00366	CcSEcCtD
Dihydroxyaluminium—Vomiting—Betamethasone—psoriatic arthritis	0.00216	0.00362	CcSEcCtD
Dihydroxyaluminium—Vomiting—Dexamethasone—psoriatic arthritis	0.00216	0.00362	CcSEcCtD
Dihydroxyaluminium—Pain—Methotrexate—psoriatic arthritis	0.00211	0.00355	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Prednisone—psoriatic arthritis	0.00202	0.0034	CcSEcCtD
Dihydroxyaluminium—Nausea—Dexamethasone—psoriatic arthritis	0.00202	0.00339	CcSEcCtD
Dihydroxyaluminium—Nausea—Betamethasone—psoriatic arthritis	0.00202	0.00339	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methotrexate—psoriatic arthritis	0.00196	0.0033	CcSEcCtD
Dihydroxyaluminium—Dizziness—Prednisone—psoriatic arthritis	0.00196	0.00328	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Methotrexate—psoriatic arthritis	0.00195	0.00328	CcSEcCtD
Dihydroxyaluminium—Vomiting—Prednisone—psoriatic arthritis	0.00188	0.00316	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00182	0.00306	CcSEcCtD
Dihydroxyaluminium—Nausea—Prednisone—psoriatic arthritis	0.00176	0.00295	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methotrexate—psoriatic arthritis	0.00169	0.00284	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methotrexate—psoriatic arthritis	0.00163	0.00274	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methotrexate—psoriatic arthritis	0.00157	0.00264	CcSEcCtD
Dihydroxyaluminium—Nausea—Methotrexate—psoriatic arthritis	0.00147	0.00246	CcSEcCtD
